Identification
NameTartaric acid
Accession NumberDB09459
TypeSmall Molecule
GroupsApproved
Description

Tartaric acid is a white crystalline organic acid that occurs naturally in many plants, most notably in grapes.Tartaric is an alpha-hydroxy-carboxylic acid, is diprotic and aldaric in acid characteristics, and is a dihydroxyl derivative of succinic acid.

Structure
Thumb
SynonymsNot Available
External IDs E 334 / E-334 / FEMA NO. 3044 / INS NO.334 / INS-334 / NSC-62778
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Baros Effervescent GranulesTyco Healthcare
BicaruvasProsana Distribuciones, S.A. De C.V.
Brioschi Childrens Effervescent AntacidBrioschi, Inc.
Brioschi Effervescent AntacidBrioschi, Inc.
E-Z-gas 2 GranulesTherapex Division De E Z Em Canada Inc
Gingera Effervescent AntacidBrioschi, Inc.
Unik Zoru PwrTherapex Division De E Z Em Canada Inc
Unik Zoru TabTherapex Division De E Z Em Canada Inc
Urasal GranulesAxxess Pharma Inc.
Categories
UNIIW4888I119H
CAS numberNot Available
WeightAverage: 150.0868
Monoisotopic: 150.016437924
Chemical FormulaC4H6O6
InChI KeyFEWJPZIEWOKRBE-JCYAYHJZSA-N
InChI
InChI=1S/C4H6O6/c5-1(3(7)8)2(6)4(9)10/h1-2,5-6H,(H,7,8)(H,9,10)/t1-,2-/m1/s1
IUPAC Name
(2R,3R)-2,3-dihydroxybutanedioic acid
SMILES
O[[email protected]]([C@@H](O)C(O)=O)C(O)=O
Pharmacology
Indication

Tartaric Acid is primarily indicated in conditions like Antiscorbutic, Antiseptic.

Structured Indications
Pharmacodynamics

Tartaric acid is used to generate carbon dioxide through interaction with sodium bicarbonate following oral administration. Carbon dioxide extends the stomach and provides a negative contrast medium during double contrast radiography. In high doses, this agent acts as a muscle toxin by inhibiting the production of malic acid, which could cause paralysis and maybe death.

Mechanism of actionNot Available
Related Articles
Absorption

Oral or parenteral doses of monosodium 14C-L(+)-tartrate (400 mg/kg) are rapidly excreted by rats and a proportion completely metabolized to CO2. The oral dose was well-absorbed.

Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Most tartarate that is consumed by humans is metabolized by bacteria in the gastrointestinal tract , primarily in the large instestine.

Route of elimination

Only about 15-20% of consumed tartaric acid is secreted in the urine unchanged.

Half lifeNot Available
ClearanceNot Available
Toxicity

Routes of Entry: Inhalation. Ingestion.

Toxicity to Animals: Lowest Published Lethal Dose: LDL [Rat - Route: oral; Dose: 7500 mg/kg LDL [Rabbit] - Route: Oral; Dose: 5000 mg/kg LDL [Dog] - Rout: Oral; Dose: 5000 mg/kg Lethal Dose/Conc 50% kill: LD50 [Mouse] - Route: Intravenous; Dose: 485 mg/kg

Other Toxic Effects on Humans: Acute Potential Health Effects: Skin: Causes skin irritation Eyes: Causes eye irritation Inhalation: Causes respiratory tract irritation Ingestion: Causes gastrointestinal tract irritation with nausea, vomiting and diarrhea. May affect kidneys (kidney damage), blood, and behavior (convulsions, somnolence), and respiration. Chronic Potential Health Effects: Ingestion: Repeated or prolonged ingestion may cause lesions of the mouth, gastric ulcers, gastrointestinal hyperacidity, and symptoms similar to those of metal fume fever - flu-like condition with fever, chills, sweats, nausea, vomiting, muscle aches, pains, and weakness. Skin: Repeated or prolonged skin contact may cause skin ulcerations or lesions.

Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions Not Available
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Chasseaud LF, Down WH, Kirkpatrick D: Absorption and biotransformation of L(+)-tartaric acid in rats. Experientia. 1977 Aug 15;33(8):998-9. [PubMed:891842 ]
  2. Pubchem [Link]
  3. Wikipedia [Link]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials Not Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Powder, for solutionOral
Granule, effervescentOral
PowderOral
TabletOral
PricesNot Available
PatentsNot Available
Properties
StateNot Available
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility161.0 mg/mLALOGPS
logP-1.3ALOGPS
logP-1.8ChemAxon
logS0.03ALOGPS
pKa (Strongest Acidic)2.72ChemAxon
pKa (Strongest Basic)-4.3ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area115.06 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity26.21 m3·mol-1ChemAxon
Polarizability11.33 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
GC-MSGC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)splash10-0002-0930000000-19235937e21066a9c484View in MoNA
GC-MSGC-MS Spectrum - GC-MS (4 TMS)splash10-000f-0961000000-559c31b016f4fb3700d2View in MoNA
GC-MSGC-MS Spectrum - EI-Bsplash10-0007-0961000000-1b17d674621eb9d88c3cView in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 10V, Negative (Annotated)splash10-000b-7900000000-d247ec12b77f427e9a76View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 25V, Negative (Annotated)splash10-05fu-9000000000-4bf01ad116d24a453817View in MoNA
LC-MS/MSLC-MS/MS Spectrum - Quattro_QQQ 40V, Negative (Annotated)splash10-0006-9000000000-4da65da10f3a34f77688View in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, Negativesplash10-0002-0900000000-ecb902731b9f6eb3764dView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, Negativesplash10-0072-9700000000-1e8e6f410c1d71af856eView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, Negativesplash10-00di-9000000000-f13ad2560d3e6818db9cView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, Negativesplash10-05fu-9000000000-f46a01eb933ba6fbceacView in MoNA
LC-MS/MSLC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, Negativesplash10-0006-9000000000-08dec35ca6a80add253aView in MoNA
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,1H] 2D NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
Taxonomy
ClassificationNot classified

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
catalytic activity
General Function:
Udp-galactose:beta-n-acetylglucosamine beta-1,3-galactosyltransferase activity
Specific Function:
Involved in the biosynthesis of L2/HNK-1 carbohydrate epitope on glycoproteins. Can also play a role in glycosaminoglycan biosynthesis. Substrates include asialo-orosomucoid (ASOR), asialo-fetuin, and asialo-neural cell adhesion molecule. Requires sphingomyelin for activity: stearoyl-sphingomyelin was the most effective, followed by palmitoyl-sphingomyelin and lignoceroyl-sphingomyelin. Activit...
Gene Name:
B3GAT1
Uniprot ID:
Q9P2W7
Molecular Weight:
38255.675 Da
References
  1. UniProt [Link]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
catalytic activity
General Function:
Zinc ion binding
Specific Function:
Hydroxylates HIF-1 alpha at 'Asp-803' in the C-terminal transactivation domain (CAD). Functions as an oxygen sensor and, under normoxic conditions, the hydroxylation prevents interaction of HIF-1 with transcriptional coactivators including Cbp/p300-interacting transactivator. Involved in transcriptional repression through interaction with HIF1A, VHL and histone deacetylases. Hydroxylates specif...
Gene Name:
HIF1AN
Uniprot ID:
Q9NWT6
Molecular Weight:
40285.25 Da
References
  1. UniProt [Link]
  2. HMDB [Link]
Drug created on November 30, 2015 12:10 / Updated on June 24, 2017 13:32